Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT04381260 Completed - Clinical trials for Cardiovascular Diseases

RUral dispaRities in prehospitAL STEMI

Start date: December 15, 2020
Phase:
Study type: Observational [Patient Registry]

Rural Americans are more likely to be unhealthy, older, living in poverty, uninsured, and medically underserved. The CDC has made achieving health equity and improving cardiovascular health for rural Americans one of their Healthy People 2020 overarching goals. ST-Elevation Myocardial Infarction (STEMI) is a life-threatening cardiovascular emergency that frequently affects people without warning within the communities the Participants live and work. Patients with STEMI have a linear relationship between first medical contact to Percutaneous Coronary Intervention (PCI) time and mortality. Delays are particularly important in STEMI patients with cardiogenic shock, who experience an excess 3.3 deaths per 100 for every 10 minute delay to PCI (for PCI times between 60-180 minutes). Delayed PCI is also associated with a higher rate of long term morbidity, including congestive heart failure and repeat MI. Unfortunately, many rural EMS agencies fail to consistently achieve the recommended 90 minute PCI time goal. Rural agencies are less likely than urban/suburban agencies to meet time goals and this disparity exposes rural patients to excess morbidity and mortality. The American College of Cardiology/American Heart Association (ACC/AHA) endorse the need for prehospital strategies to reduce total ischemic time, particularly in rural settings.

NCT ID: NCT04359875 Completed - Clinical trials for Cardiovascular Diseases

A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment

COVIQuest
Start date: April 30, 2020
Phase: N/A
Study type: Interventional

Following the announcement of the containment of the population due to the COVID-19 epidemic on March 17, 2020 in France, a notable decrease in the number of consultations in general practice was reported. Patients no longer contact their general practitioner, including those with regular follow-up for one or more chronic conditions. This observation raised worries since it could lead to delay or failure in detecting decompensations / complications of these chronic conditions by a lack of recourse to care. Thus, an urgent message from the National Health Department (Direction Générale de la Santé - DGS) was adressed on April 8, 2020 to the health professionals regarding the organization of care aside from COVID-19. The main recommendation was "that the personal physician or the corresponding specialist should contact the most fragile patients with chronic condition to ensure follow-up and detect any risk of decompensation ". Such fragile patients are in great numbers, up to more than 200 for an average general practitioner. Therefore, although this recommendation is regarded as "essential in view of the health needs of the population", it will prove quite difficult to follow without the help of a skilled external assistance that can be quickly mobilized.

NCT ID: NCT04359446 Completed - Clinical trials for Cardiovascular Diseases

Laser-excimer Versus High-pressure Dilation to Treat Under-expansion of the Stent

LASER EXPAND
Start date: September 12, 2020
Phase: N/A
Study type: Interventional

The laser-excimer technology could be an essential tool to correct the under-expansion of the stent once it has been implanted unless severe calcification. The laser-excimer technology achieves a greater minimum luminal area when treating an infra-expanded stent, when compared with the results obtained with the simple dilatation at high or very high pressure.

NCT ID: NCT04357301 Completed - Clinical trials for Cardiovascular Diseases

Tight Closed-loop Systolic Arterial Pressure Control

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this case series is to evaluate the performance of a novel closed-loop (automated) vasopressor administration system that delivers norepinephrine using feedback from standard operating room hemodynamic monitoring (EV1000 monitoring device, Edwards Lifesciences, Irvine, USA).

NCT ID: NCT04354051 Completed - Clinical trials for Cardiovascular Diseases

The Nitrite and Coronary Flow Study

Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a pharmacodynamic proof of concept study investigating the physiological effects of systemic infusion of nitrite on coronary blood flow using MRI.

NCT ID: NCT04342468 Completed - Hypertension Clinical Trials

Blood Pressure Variability and Cardiovascular Disease Events in Patients With Hypertension

BPV
Start date: July 14, 2017
Phase:
Study type: Observational

Cardiovascular Disease (CV) including stroke is the leading cause of death in Malaysia Hypertension is a major contributor to this. Prevalence of hypertension in Malaysia is high (42%) in adults age 30 years or older. Besides the actual blood pressure (BP) level recently, blood pressure variability (BPV) has been recognized as an independent and strong predictor of CV events especially strokes. However, data on the BP variability and its relationship to CV events is very limited in Asia, particularly in Malaysia. Hence the investigators aim to study BPV and its relationship to CV events in treated hypertensive patients

NCT ID: NCT04340388 Completed - Vascular Diseases Clinical Trials

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Start date: September 17, 2020
Phase: Phase 4
Study type: Interventional

The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir based regimen on on lipid and metabolic profiles, renal function, body composition, vascular function and diet.

NCT ID: NCT04336306 Completed - Clinical trials for Cardiovascular Diseases

Virtual Reality-based Therapy and Barriers in Cardiac Patients

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the chronic hemodynamic and autonomic repercussions of the insertion of VRBT in CR. To qualitatively analyze the perception of patients and physiotherapists regarding the use of VRBT, as well as their association with CR, and through a new questionnaire that takes into account patients 'adherence, identifying which are the main barriers that influence patients' absences.

NCT ID: NCT04327479 Completed - Clinical trials for Cardiovascular Diseases

Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Start date: March 26, 2020
Phase:
Study type: Observational [Patient Registry]

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

NCT ID: NCT04324684 Completed - Obesity Clinical Trials

Prognostic Factors Keeping Track for COVID-19 Pneumonia

NIKE_C19
Start date: March 31, 2020
Phase:
Study type: Observational

It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.